Ertapenem
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection
Conditions
Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection
Trial Timeline
Dec 1, 2013 → Jun 1, 2015
NCT ID
NCT02041767About Ertapenem
Ertapenem is a approved stage product being developed by Merck for Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection. The current trial status is completed. This product is registered under clinical trial identifier NCT02041767. Target conditions include Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02041767 | Approved | Completed |
| NCT01159379 | Approved | UNKNOWN |
| NCT01203046 | Phase 2/3 | Completed |
| NCT01173068 | Pre-clinical | UNKNOWN |
| NCT00939952 | Approved | Completed |
Competing Products
20 competing products in Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection